Get to know our clinical trials
Study to evaluate different doses of BI 1831169 alone and in combination with ezabenlimab in people with different types of advanced cancer (solid tumors).
THE AIM OF THE STUDY IS TO FIND OUT THE HIGHEST AMOUNT OF BI 1831169 THAT CAN BE ADMINISTERED WITHOUT TOO MANY SIDE EFFECTS, BOTH ALONE AND IN COMBINATION WITH ANOTHER DRUG (EZABENLIMAB), AS WELL AS TO OBSERVE THE EFFECT IT MAY HAVE ON CANCEROUS TUMORS AND ON THE BODY.
Technical Summary
- PHASE I, OPEN-LABEL, DOSE-ESCALATION TRIAL OF BI 1831169 IN MONOTHERAPY AND IN COMBINATION WITH EZABENLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: 2020-003902-30
- Protocol number: 1456-0001
- Promoter: Boehringer Ingelheim España, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.